About Cue Biopharma Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.cuebiopharma.com/
Frequently Asked Questions
What is the 52-week range for CUE?
The 52-week high is $45.5 and the 52-week low is $4.97.
What is the P/E ratio for CUE?
The P/E ratio data is currently unavailable.
What is the dividend yield for CUE?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -1032.19%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -435.83%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.05.
Analyst Recommendation Trends
Wall Street analyst consensus for CUE over the last few months:
Latest CUE News
Cue Biopharma’s CUE-221 Hits Phase II Goals, Shows Durable CSU Response
Cue Biopharma (NASDAQ:CUE) reported positive top-line results from a Phase II trial of CUE-221 in patients with moderate-to-severe chronic spontaneous urticaria, or CSU, whose disease was inadequately controlled with H1 antihistamines. The randomized, double-blind, placebo-controlled study evaluate
Cue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart?
Cue Biopharma, Inc. (NASDAQ:CUE) reported positive Phase 2 results for CUE-221 on September 20. The randomized, double-blind study enrolled 145 patients in China with moderate to severe chronic spontaneous urticaria, or chronic hives, inadequately controlled by H1 antihistamines. At week 12, complete hive resolution occurred in 54% of patients receiving 4 mg/kg CUE-221 versus 11% […]
Cue Biopharma, Inc. (CUE) Discusses Positive Phase II Top Line Results for CUE-221 in Chronic Spontaneous Urticaria - Slideshow
2026-09-24. The following slide deck was published by Cue Biopharma, Inc.
An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.
Let's take a look at the stocks that are in motion in today's session.
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
Which stocks are experiencing notable movement on Monday?
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Which stocks are gapping on Monday?
The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs.
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Greenland Mines (NASDAQ:GRML) stock rose 232.6% to $9.48 during Monday's regular session. The company's market cap stands at $9.0 million. GRAIL (NASDAQ:GRAL) shares moved upwards by 31.47% to $106.19.
Discover the top movers in Monday's pre-market session.
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Cue Biopharma Shares Jump 41.6% Premarket Following Phase 2 Trial Results
Cue Biopharma (NASDAQ:CUE) shares rose 41. 6% in premarket trading after the company reported positive topline results from a Phase 2 clinical trial evaluating CUE-221 in patients with moderate to severe chronic spontaneous urticaria.
What's Going on With Cue Biopharma Stock on Monday?
Cue Biopharma reports Phase 2 CUE-221 trial results in chronic hives, showing strong efficacy and favorable safety.
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Greenland Mines (NASDAQ:GRML) stock rose 108.1% to $5.93 during Monday's pre-market session. The market value of their outstanding shares is at $9.0 million. Cue Biopharma (NASDAQ:CUE) stock moved upwards
Why Lobo Technologies Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket
Lobo Technologies shares surged 32% premarket after a narrower H1 loss and higher sales; several small caps rallied while others fell sharply.
Reported Sunday, Cue Biopharma's CUE-221 Shows 60% Complete Hives Resolution Twelve Weeks Off Treatment At 4 Mg/Kg In Phase 2 Chronic Spontaneous Urticaria Study Versus 24% For Omalizumab In Post Hoc Analysis
Primary endpoint and the key secondary endpoint were met with high statistical significance and CUE-221 demonstrated an overall favorable safety profileClinically different efficacy profile observed relative to XOLAIR®
Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria
Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling studyPrimary endpoint and the key secondary endpoint were met with high statistical significance and CUE-221 demonstrated an overall favorable safety profileClinically different efficacy profile observed relative to XOLAIR® (omalizumab) highlights potential for a fundamental mechanism-based biological differenceCue Biopharma to host conference
This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Analysts initiated bullish coverage on TRAX, BGSI, NPCE, CUE and NGVC, assigning Outperform/Buy ratings with price targets from $18 to $120.
B. Riley Securities Initiates Coverage On Cue Biopharma with Buy Rating, Announces Price Target of $83
B. Riley Securities analyst Mayank Mamtani initiates coverage on Cue Biopharma (NASDAQ:CUE) with a Buy rating and announces Price Target of $83.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-13 | Meluzio Michael Vincent | -13,647 | - | - |
| 2026-08-13 | Meluzio Michael Vincent | -3 | $31.13 | $93 |
| 2026-08-13 | Meluzio Michael Vincent | -4,106 | $30.35 | $124,617 |
| 2026-08-13 | Meluzio Michael Vincent | -1,519 | $29.37 | $44,613 |
| 2026-08-13 | Meluzio Michael Vincent | +13,647 | - | - |
| 2026-08-13 | Ray Sumita | -18,196 | - | - |
| 2026-08-13 | Ray Sumita | -4 | $31.13 | $125 |
| 2026-08-13 | Ray Sumita | -6,442 | $30.35 | $195,515 |
| 2026-08-13 | Ray Sumita | -2,383 | $29.37 | $69,989 |
| 2026-08-13 | Ray Sumita | +18,196 | - | - |
| 2026-08-13 | Lin Shao-Lee | -10,460 | $29.48 | $308,361 |
| 2026-08-13 | Lin Shao-Lee | -2,375 | $28.11 | $66,761 |
| 2026-08-13 | Lin Shao-Lee | -5,423 | $27.19 | $147,451 |
| 2026-08-12 | Lin Shao-Lee | -109,179 | - | - |
| 2026-08-12 | Lin Shao-Lee | -5,775 | $27.75 | $160,256 |
| 2026-08-12 | Lin Shao-Lee | -34,225 | $26.99 | $923,733 |
| 2026-08-12 | Lin Shao-Lee | +109,179 | - | - |
| 2026-07-30 | Ahlers James M | +51,000 | - | - |
| 2026-07-30 | Ahlers James M | +25,500 | - | - |
| 2026-07-13 | Borie Dominique Christian | +63,000 | - | - |
| 2026-07-13 | Borie Dominique Christian | +31,500 | - | - |
| 2026-07-09 | Sarraf Pasha | +18,400 | - | - |
| 2026-07-09 | Garzone Pamela | +18,900 | - | - |
| 2026-07-09 | Meluzio Michael Vincent | +40,942 | - | - |
| 2026-07-09 | Meluzio Michael Vincent | +40,942 | - | - |
| 2026-07-09 | Meehan Viola Mong | +21,800 | - | - |
| 2026-07-09 | Sarraf Pasha | +21,800 | - | - |
| 2026-07-09 | Garzone Pamela | +21,800 | - | - |
| 2026-07-09 | Camardo Daniel A. | +21,800 | - | - |
| 2026-07-09 | Lin Shao-Lee | +327,537 | - | - |
| 2026-07-09 | Lin Shao-Lee | +327,537 | - | - |
| 2026-07-09 | Ray Sumita | +54,589 | - | - |
| 2026-07-09 | Ray Sumita | +54,589 | - | - |
| 2026-06-01 | Lin Shao-Lee | +45,453 | - | - |
| 2026-06-01 | Lin Shao-Lee | +90,906 | $11 | $999,966 |
| 2026-06-01 | Lin Shao-Lee | +45,453 | - | - |
| 2026-06-01 | Lin Shao-Lee | +90,906 | $11 | $999,966 |
| 2026-05-30 | Camardo Daniel A. | +1,626 | - | - |
| 2026-05-30 | Meehan Viola Mong | +1,626 | - | - |
| 2026-05-03 | Lin Shao-Lee | +655,074 | - | - |
| 2026-05-03 | Lin Shao-Lee | +327,537 | - | - |
| 2026-04-09 | Sandercock Colin | +200,000 | - | - |
| 2026-04-09 | Warren Lucinda | +250,000 | - | - |
| 2026-04-09 | Baker Daniel G. | +100,000 | - | - |
| 2026-01-02 | Morich Frank | +24,400 | - | - |
| 2026-01-02 | Garzone Pamela | +24,400 | - | - |
| 2026-01-02 | Verheyen Patrick | +24,400 | - | - |
| 2026-01-02 | Sarraf Pasha | +24,400 | - | - |
| 2026-01-02 | Kiener Peter A | +24,400 | - | - |
| 2026-01-02 | Broadfoot Jill Marie | +24,400 | - | - |
| 2025-12-30 | Sarraf Pasha | +77,417 | $0.3016 | $23,349 |
| 2025-12-30 | Sarraf Pasha | +78,116 | $0.3114 | $24,325 |
| 2025-12-30 | Sarraf Pasha | +86,947 | $0.3174 | $27,597 |
| 2025-12-30 | Sarraf Pasha | +77,148 | $0.3003 | $23,168 |
| 2025-12-30 | Sarraf Pasha | +4,229 | $0.3094 | $1,308 |
| 2025-12-03 | Sandercock Colin | +70,000 | - | - |